Morphimmune Announces Merger With Immunome and $125 Million Private Investment

San Diego – July 5, 2023 – Cooley advised Morphimmune, a private biotechnology company, on its definitive merger agreement with Immunome. Partners Tom Coll, Barbara Borden and Carlos Ramirez led the Cooley team advising Morphimmune.

Immunome will acquire Morphimmune through a reverse subsidiary merger that is intended to be a tax-free reorganization. The companies also announced an oversubscribed private placement investment of $125 million – with participation from Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners and other top institutional investors – which will support development of a combined pipeline expected to submit three investigational new drug applications within 18 months of closing. Clay B. Siegall, PhD, current Morphimmune president and CEO, will serve as chairman and CEO of the combined company.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.